Detection and Identification of Microorganisms

Detection and Identification of Microorganisms

Detection and Identification of Microorganisms Chapter 12 Target Microorganisms for MolecularBased Testing Those that are difficult or time-consuming to isolate e.g., Mycobacteria Hazardous organisms e.g., Histoplasma, Coccidioides Those without reliable testing methods

e.g., HIV, HCV High-volume tests e.g., S. pyogenes, N. gonorrhoeae, C. trachomatis Applications of Molecular-Based Testing in Clinical Microbiology Rapid or high-throughput identification of microorganisms Detection and analysis of resistance genes Genotyping Classification Discovery of new microorganisms

Specimen Collection Preserve viability/nucleic acid integrity of target microorganisms. Avoid contamination. Maintain appropriate time and site of collection (blood, urine, other). Use proper equipment (coagulant, wood, or plastic swab shafts). Commercial collection kits are available. The Clinical and Laboratory Standards Institute (CLSI) has guidelines for proper specimen handling. Sample Preparation Consider the specimen type (stool, plasma, CSF). Consider the number and type of organisms in the sample. Inactivate inhibitors (acidic polysaccharides in sputum or polymerase

inhibitors in CSF). Inactivate RNases. PCR Detection of Microorganisms: Quality Control PCR and other amplification methods are extremely sensitive and very specific. For accurate test interpretation, use proper controls. Positive control: positive template

Negative control: negative template Amplification control: omnipresent template unrelated to target Reagent blank: no template present PCR Quality Control: Internal Controls Homologous extrinsic Controls for amplification Heterologous extrinsic Controls for extraction and amplification Heterologous intrinsic

Human gene control PCR Quality Control: Internal Controls Homologous extrinsic Controls for amplification Heterologous extrinsic Controls for extraction and amplification Heterologous intrinsic Human gene control

Target sequence Sensitivity vs Specificity Sensitivity and specificity are statistical measures of the performance of a test. Sensitivity (also called the true positive rate) measures the proportion of actual positives which are correctly identified as such (e.g. the percentage of sick people who are correctly identified as having the condition). Specificity measures the proportion of negatives which are correctly identified as such (e.g. the percentage of healthy people who are correctly identified as not having the condition, sometimes called the true negative rate).

Sensitivity vs Specificity When screening for a disease, sensitivity is more important (you can confirm with a more specific test later) When confirming a disease, specificity is more important Quality Control: False Positives Contamination: check reagent blank Dead or dying organisms: retest 36 weeks after antimicrobial therapy Detection of less than clinically significant levels Quality Control: False Negatives Improper collection, specimen handling

Extraction/amplification failure: check internal controls Technical difficulties with chemistry or instrumentation: check method and calibrations Detection of Bacteria Respiratory Diseases Respiratory infections are responsible for significant numbers of infections and deaths worldwide. These infections are easily spread by inhalation Bordetella (Whooping Cough) Bordetella pertussis is a Gram-negative, aerobic coccobacillus B. pertussis is nonmotile. Its virulence factors include pertussis toxin,

filamentous hemagglutinin, and tracheal cytotoxin. Bordetella In the US, it killed 5,000 to 10,000 people per year before a vaccine was available. Worldwide in 2000, according to the WHO, around 39 million people were infected annually and about 297,000 died. Because of concerns regarding the vaccine, numbers continue to be high Bordetella There are three species that cause most of the pertussis seen in humans: B. pertussis causes the most severe whooping cough in children.

B. parapertussis and B. holmesii cause a less severe whopping cough. Bordetella In view of its enormous sensitivity and specificity rapid PCR based detection of B. pertussis has attracted much attention in recent years. The chromosomal regions that have been used as targets for B. pertussis specific PCR include : the adenylate cyclase toxin (ACT) gene

a region upstream of the porin gene , Pertussis toxin (PT) promotor region, and repeat insertion sequences. Among these, repeat insertion sequence IS481 region being present in multiple copies (80100) in B. pertussis, is a target of choice for amplification and detection with greater sensitivity. Bordetella However, B. holmesii also contains regions homologous to IS481 . Thus PCR targeting IS481 will generate a positive DNA product for both B. pertussis and B. holmesii as observed. As a result it although will provide high sensitivity, it will lack

specificity. However, since there are two single nucleotide changes (A/ C and C/T variation) in alleles of B. holmesii genome; a DNA probe can be diagnostic. Bordetella However, there is another insertion sequence, (IS 1001), that is present in B. holmesii but not in B. pertussis. Thus, testing for both insertion points will give a differential diagnosis. Tuberculosis The presence of acid-fast-bacilli (AFB) on a sputum smear or other specimen often indicates TB disease. Acid-fast microscopy is easy and quick, but it does not confirm a diagnosis of TB because some acidfast-bacilli are not Mycobacterium tuberculosis.

Therefore, a culture is done on all initial samples to confirm the diagnosis. (However, a positive culture is not always necessary to begin or continue treatment for TB.) A positive culture for M. tuberculosis confirms the diagnosis of TB disease. Tuberculosis Although sputum smears are the gold standard for diagnosis of tuberculosis, sensitivity in HIV/TB coinfection cases is low, indicating a need for alternative methods. Also culture can take as long as 3 weeks. Urine is being increasingly evaluated. A new method for detecting Mycobacterium tuberculosis (MTB) uses combined IMS/ATP assay.

Tuberculosis If the smear is positive, PCR or gene probe tests can distinguish M. tuberculosis from other mycobacteria. Target probe is the 16S rRNA sequence. Turnaround is reduced to about 2-3 hours. But sensitivity is not good enough for clinical specimens Tuberculosis Urine is being increasingly evaluated. A new method for detecting Mycobacterium tuberculosis (MTB) uses combined IMS/ATP assay.

Tuberculosis Immunomagnetic separation (IMS) is used to concentrate and recover pathogenic mycobacteria, including MTB . IMS also enables specific target capture and decreases particulate interference in detection assays. Tuberculosis ATP bioluminescence assays have demonstrated utility in bacteriuria (bacteria in urine) screening , quality control of BCG vaccines, and MTB antibiotic susceptibility testing. The determination of ATP using bioluminescence uses the ATP dependency of the light emitting luciferase catalyzed oxidation of luciferin for the measurement of extremely low concentrations of ATP.

Luminescence is measured using a luminometer. Tuberculosis Combining immunocapture with an ATP-based cell viability assay can provide rapid, specific, semiquantitative detection of live cells. The method can provide rapid, specific detection of MTB in urine. The method is easy to perform and could be used in settings where the rate of HIV/TB co-infection is high. Detection of bacterial STDs Historically, the diagnosis of sexually transmitted diseases (STDs) has been difficult. The introduction of molecular biology techniques in microbiological diagnosis and their application to non-invasive samples

has produced significant advances in the diagnosis of these diseases. Overall, detection of Neisseria gonorrhoeae by molecular biology techniques provides a presumptive diagnosis and requires confirmation by culture in areas with a low prevalence. For Chlamydia trachomatis infections, these techniques are considered to be the most sensitive and specific procedures for mass screening studies, as well as for the diagnosis of symptomatic patients. Detection of bacterial STDs Diagnosis of Mycoplasma genitalium infection by culture is very slow and consequently molecular techniques are the only procedures that can provide relevant diagnostic information. For Treponema pallidum, molecular techniques can provide direct

benefits in the diagnosis of infection. Molecular methods are advisable in Haemophilus ducreyi, because of the difficulties of culture and its low sensitivity. Detection of Viruses Because of the difficulty in growing and identifying viruses, it is this field that have benefitted tremendously from the introduction of molecular based methods. Viruses Classical methods of detection include antibody detection, antigen detection, and culture. Molecular methods of detection include target, probe, and signal

amplification. Tests are designed for identification of viruses, determination of viral load (number of viruses per mL of fluid), and genotyping by sequence analysis Classic Antibody detection IgM and IgG Levels IgM is the first antibody produced by the body when it is exposed to a virus. The IgM test is used to screen for early detection of infection and is used to diagnose the disease during onset. IgG antibodies develop later and remain present for many years, usually for life, and protect against further infection by the same virus.

HIV Molecular testing is important in HIV, not only for detection of the disease, but also continued monitoring of disease treatments. Detection of HIV The first marker that becomes detectable after infection is the HIV RNA, indicated by the green line. This is detectable by current molecular methods at about 11 days from the time of infection or exposure to HIV. The second marker that becomes detectable in the laboratory is the HIV p24 antigen, indicated in the purple line. This is detectable by day 16 from exposure. And finally, the HIV antibodies that are detectable by current commercial assays occur at about day 22 from the date of infection. So the most widely used serologic tests, which are HIV antibody screening tests, are actually

the least sensitive in picking up HIV infection compared to the other 2 markers. Detection of HIV There are basically 2 windows of HIV infection for detection. The first is the seroconversion window, which starts from time of infection, indicated by the first arrow on the left-hand side of the timeline, to the time point where antibody becomes detectable. So, this seroconversion window period actually includes the eclipse period and the acute infection period. The eclipse period is the period at which time that only molecular tests can detect the presence of HIV RNA. The acute infection is the period between viral infection detectable by

molecular tests and a serologic response, which is detectable by serologic assays. Now the incidence window is the period from the time of antibody detection first from the infected individual until a specific time point where the serologic assay can determine recent infection. So that particular window period is also known as the recent infection. And, after this assay-specific detection point for recent infection, we see long-standing HIV infection. Detection of HIV The most widely used methods for HIV detection are the ELISA assays, the enzymelinked immunosorbant assays, which can come in the form of enzyme immunoassay or chemoluminescent immunoassay. They can detect either HIV-1 antibodies, or HIV-2 antibodies, or HIV-1 p24 antigen, or a combination of HIV-1 and -2; and then lastly the

fourth generation serologic test is a combination of antibody and p24 antigen. And, basically, there are 2 methods, the immunochromatography method, as well as the membrane immunoconcentration method. These rapid test devices are available to detect either HIV-1 antibodies alone, HIV-2 antibodies alone, or a combination of HIV-1 and -2 antibodies. The final group of serologic tests are the so-called supplemental tests, also known as confirmatory tests for HIV-1 and -2 antibodies. And there are essentially 2 methods that are commercially available: one is the Western blot and the other is the Immunoblot. Detection of HIV Early in the epidemic of HIV infection, the first tests that were available for diagnosis or detection of HIV are viral cultures using CD4 cells; these are the human helper T cells that are infected by

HIV viruses. And, using these viral cultures, one is able to detect production of viral p24 antigens in the supernatant of cell cultures from CD4 cell lines. PCR assays for qualitative and quantitative detection of HIV-1 and -2 are also available. For qualitative PCR assays, one could detect HIV-1 proviral DNA. This is the DNA that is incorporated into the CD4 whole cells, DNA that belong to HIV-1 viral genome. One could also detect a combination of HIV proviral DNA and RNA and also laboratory-developed assays, particularly in certain research investigator laboratories, one could also design a qualitative detection of HIV-2 RNA. For quantitative assays, there are commercially available and FDA- approved assays for quantifying HIV-1 RNA, and then there are laboratory-developed assays for quantifying HIV-2 RNA. Two other commercial laboratory tests available utilize transcription-mediated amplification for qualitative detection of HIV-1 RNA, and the branched DNA method, which utilizes signal amplification for quantitation of HIV-1 RNA.

Treatment of HIV In an HIV infected individual, the concentration of virus in the bloodstream or vi ral load (VL) can be a valuable tool for the clinical management of the infection. Broadly, there are three clinical uses for quantifying HIV in plasma: diagnosing acute HIV infection determining prognosis and disease progression therapeutic monitoring. Treatment of HIV Unlike antibody detection, which is confounded by the trans placental transfer of maternal IgG antibodies, VL can also be useful in di

agnosing babies born to HIVpositive mothers. However monitoring VL is most relevant as a biomarker to monitor the therapeutic efficacy. Quantifying viral load in plasma enables a clinician to assess the success of treatment and detec t treatment failure prior to the onset of clinical symptoms. Test Performance Features for Viral Load Measurement Characteristic Description Sensitivity

Lowest level detected at least 95% of the time Accuracy Ability to determine true value Precision Reproducibility of independently determined test results Specificity

Positive results are true positives Linearity A serial dilution of standard curve closely approximates a straight line Flexibility Accuracy of measurement of virus regardless of sequence variations

Hepatitis Viral hepatitis, including hepatitis A, hepatitis B, hepatitis C, hepatitis D and hepatitis E are distinct diseases that affect the liver and have different hepatitis symptoms and treatments. Each virus is different and the only commonality between them is that they all cause an inflammation of the liver. There is more concern over hepatitis B and C because they are bloodborne pathogens. Hepatitis Old methods for detecting hepatitis revolved around antibody and antigen detection. For example the next couple of pages of this powerpoint describe the markers looked for in diagnosing Hepatitis B.

Hepatitis B Ags and Abs Hepatitis B surface antigen Protein that is present on (HBsAG) the surface of the virus; will be present in the blood with acute and chronic HBV infections Hepatitis B surface antibody (anti-HBs) Antibody produced in

response to HBV surface antigen; levels in the blood rise during the recovery phase. Often used to screen for and detect HBV infections; earliest indicator of acute hepatitis B and frequently identifies infected people before symptoms appear; undetectable in the blood during the recovery

period; it is the primary way of identifying those with chronic infections. Used to detect previous exposure to HBV; Hepatitis B Ags and Abs Anti-hepatitis B core (antiHBc), IgM Anti-hepatitis B core (antiHBc), Total IgM antibody to the hepatitis B core antigen

(The hepatitis B core antigen is present only in infected liver cells; it cannot be detected in the blood.) Both IgM and IgG antibodies to hepatitis B core antigen First antibody produced after infection with HBV; used to detect acute infection

Can be used to help detect acute and chronic HBV infections; it is produced in response to the core antigen and usually persists for life. Hepatitis B Ags and Abs Hepatitis B e-antigen (HBeAG) Protein produced and

released into the blood by actively replicating hepatitis B virus Anti-hepatitis Be antibody (Anti-HBe) Antibody produced in response to the hepatitis Be antigen Unlike the surface antigen, the e-antigen is found in

the blood only when the HBV virus is actively replicating. HBeAg is often used as a marker of ability to spread the virus to other people (infectivity). In those who have recovered from acute hepatitis B infection, antiHBe will be present along with anti-HBc and anti-HBs. In those with chronic hepatitis B, anti-HBe can be used to monitor the

infection and treatment. New methods of hepatitis detection are now available for all of the various types of hepatitis. Using nucleic acid detection has allowed much earlier detection of the viruses and has decreased the window for detection down from 90 days to less than one week after infection. Antimicrobial Agents Inhibit growth (-static); e.g., bacteriostatic, fungistatic Kill organisms (-cidal); e.g., bacteriocidal, fungicidal, viricidal Antimicrobial agents are classified by 1. -static/-cidal

2. Mode of action 3. Chemical structure Antimicrobial Agents (Sites of action) Mechanisms for Development of Resistance to Antimicrobial Agents Enzymatic inactivation of agent Altered target Altered transport of agent in or out Acquisition of genetic factors from other resistant organisms

Advantages of Molecular Detection of Resistance to Antimicrobial Agents Mutated genes are strong evidence of resistance. Rapid detection without culturing Direct comparison of multiple isolates in epidemiological investigations Molecular Epidemiology Epidemic: rapidly spreading outbreak of an infectious disease Pandemic: a disease that sweeps across wide geographical areas Epidemiology: collection and analysis of environmental, microbiological, and clinical data

Molecular Epidemiology Phenotypic analysis measures biological characteristics of organisms. Molecular epidemiology is a genotypic analysis targeting genomic or plasmid DNA. Species-, strain-, or type-specific DNA sequences are the sources of genotype information. Pulsed-Field Gel Electrophoresis (PFGE) M O 1

2 3 4 5 6 M O 1 2 3 4 5 6

O = outbreak strain 16 = isolates = changes from outbreak strain Criteria for PFGE Pattern Interpretation: Rule of Three Category Genetic Differences*

Fragment Differences* Epidemiological Interpretation Indistinguishable 0 0 Test isolate is the same

strain as the outbreak strain. Closely related 1 23 Test isolate is closely related to the outbreak strain.

Possibly related 2 46 Test isolate is possibly related to the outbreak strain. Different >3

>6 Test isolate unrelated to the outbreak. *Compared to the outbreak strain Interspersed Repetitive Elements REP sequence inverted repeat .GTGAATCCCCAGGAGCTTACATAAGTAAGTGACTGGGGTGAGCG. ERIC sequence inverted repeat

GCC G/T GATGNCG G/A CG C/T NNNNN G/A CG C/T CTTATC C/A GGCCTAC PCR amplification priming outward from repetitive elements generates strainspecific products. Isolate A Isolate B M A B

Is the unknown (U) strain A or B? M A B U Other Genotypic Methods Used to Type Organisms Plasmid fingerprinting with restriction enzymes

RFLP analysis Amplified fragment length polymorphism (AFLP) Interspersed repetitive elements Ribotyping spa typing Multilocus sequence typing Comparison of Molecular Epidemiology Methods Method Typing Capacity

Discriminatory Power Reproducibility Ease of Use Ease of Interpretation Plasmid

analysis good good good high good PFGE

high high high moderate good moderate Genomic

RFLP high good good high moderate poor

Ribotyping high high high good high PCR-RFLP

good moderate good high high RAPD

high high poor high goodhigh AFLP high

high good moderate high Repetitive elements good

good high high high Sequencing high

high high moderate goodhigh Viral Genotyping Viral genes mutate to overcome antiviral agents. Gene mutations are detected by sequencing. Primary resistance mutations affect drug sensitivity but may slow viral growth.

Secondary-resistance mutations compensate for the primaryresistance growth defects. Summary Molecular-based methods offer sensitive and direct detection of microorganisms. Due to high sensitivity and specificity, proper quality control is critical for molecular testing. Several molecular methods are used to type bacterial strains in epidemiological investigations. Target, probe, or signal amplification procedures are also used to determine viral load.

Recently Viewed Presentations

  • Health Policy - Pay for Value - Iowa Chapter of HIMSS

    Health Policy - Pay for Value - Iowa Chapter of HIMSS

    Health Policy - Pay for Value - Impact on Health Information Technology . Paul Mulhausen, MD, MHS. Chief Medical Officer, Telligen. Disclosure. Dr. Mulhausen is employed by Telligen, a Health Management Firm. ... 21st Century Cures Act, December 2016.
  • Microsoft Azure Platform - Department of Computer Science ...

    Microsoft Azure Platform - Department of Computer Science ...

    November 3rd, 2010. COMS W6998-6. Microsoft Azure Platform - Today, I will talk about Microsoft's Cloud Computing Platform, called Azure. The word "Azure" means a bluish color, reminding you of the sky and the clouds.
  • The Victorian Age 1832-1900

    The Victorian Age 1832-1900

    The Victorian Age 1832-1900 An Introduction Oscar Wilde (1854-1900) The Comedic Ladder Comedy of Ideas (high comedy) Characters argue about ideas like politics, religion, sex, marriage. They use wit, their clever language to mock their opponent in an argument. This...
  • Clinical Aspects of Gout ICD-9-CM Coordination and Maintenance

    Clinical Aspects of Gout ICD-9-CM Coordination and Maintenance

    Clinical Aspects of Gout ICD-9-CM Coordination and Maintenance Committee Meeting September 24-25, 2008 Joseph D. Croft, Jr, MD, FACP, MACR
  • Smarter Buildings Smarter Balancing Andy Stadheim, PE Andy.stadheim@buildingstart.com

    Smarter Buildings Smarter Balancing Andy Stadheim, PE [email protected]

    Building Information Modeling. Building Information . Modeling (BIM) is the process of generating and managing building data during its life cycle [1]. Typically it uses three-dimensional, real-time, dynamic building modeling software to increase productivity in building design and construction. [2]
  • Earthquakes  Causes - tectonics and faults  Magnitude -

    Earthquakes Causes - tectonics and faults Magnitude -

    The Richter scale nomogram Locating the epicentre: X, Y and Z are seismograph stations Earthquake magnitude: scales based on rupture dimensions (equivalent to energy released ) Mo= seismic moment. = m * A * d, where m is the shear...
  • Abbott Diagnostics - over of valuable contributions to

    Abbott Diagnostics - over of valuable contributions to

    At first, the only test method available was the test that Blumberg and the others had used, an agar gel diffusion technique, AGD, also called the Ouchterlony method, shown here. It was a simple test to perform, but the visual...
  • Ionic Equations - Mole Cafe

    Ionic Equations - Mole Cafe

    Does not indicate ionic character _____ equation - shows all ions. ... (Metathesis) Synthesis # 1 Metal oxide + nonmetal oxide salt (Not Redox) Synthesis # 1 Example Sulfur dioxide gas is passed over solid calcium oxide Synthesis # 2...